Alexandria Real Estate Equities (ARE)

The company’s portfolio is concentrated in major research clusters where universities, hospitals, venture capital, large drugmakers and emerging science companies tend to operate close together. Key markets include Greater Boston, the San Francisco Bay Area, San Diego, New York City, Seattle, Maryland, the Research Triangle, Texas and Canada. These locations are important because life science tenants often require purpose-built space, access to specialist labour, and proximity to academic and clinical partners.

Alexandria’s properties typically include laboratory, office and collaborative space that can support research and development activity from early-stage discovery through to larger-scale corporate operations. The REIT’s business model is based on leasing this space to tenants, investing in new developments or redevelopments, and maintaining a portfolio that is aligned with long-term demand for scientific innovation infrastructure.

As a listed REIT, Alexandria gives public market investors exposure to a niche segment of commercial real estate with different demand drivers from traditional office property. Its performance is linked to occupancy levels, rental rates, development execution, financing costs and the health of the life sciences funding environment. The company is distinctive for its focus on urban innovation districts and its role as a property partner to organisations working in biotechnology, medicine, agriculture technology and related research fields.